Physician Publications

The Texas Center for Proton Therapy physicians and clinical team have more than 70 years of combined experience delivering proton therapy, making us one of the nation’s most experienced clinical staffs. Texas Center for Proton Therapy physicians have been published in leading medical journals. Below is a list of clinical articles published by Texas Center for Proton Therapy physicians.

Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model
Dalela D, Santiago-Jiménez M, Yousefi K, Karnes RJ, Ross AE, Den RB, Freedland SJ, Schaeffer EM, Dicker AP, Menon M, Briganti A, Davicioni E, Abdollah F
Journal of Clinical Oncology, 2017.
Ability of a Genomic Classifier to Predict Metastasis and Prostate Cancer-specific Mortality after Radiation or Surgery based on Needle Biopsy Specimens
Nguyen PL, Haddad Z, Ross AE, Martin NE, Deheshi S, Lam LLC, Chelliserry J, Tosoian JJ, Lotan TL, Spratt DE, Stoyanova RS, Punnen S, Ong K, Buerki C, Aranes M, Kolisnik T, Margrave J, Yousefi K, Choeurng V, Davicioni E, Trock BJ, Kane CJ, Pollack A, Davis JW, Feng FY, Klein EA
European Urology, 2017.
Genomic testing for localized prostate cancer: where do we go from here?
Loeb S, Ross AE
Current Opinions in Urology, 2017.
Use of the Prostate Health Index for detection of prostate cancer: results from a large academic practice
Tosoian JJ, Druskin SC, Andreas D, Mullane P, Chappidi M, Joo S, Ghabili K, Agostino J, Macura KJ, Carter HB, Schaeffer EM, Partin AW, Sokoll LJ, Ross AE
Prostate Cancer Prostatic Diseases, 2017.
Dynamic Contrast Enhanced MRI Improves Classification of Prostate Lesions: A Study of Pathologic Outcomes on Targeted Prostate Biopsy
Druskin SC, Ward R, Purysko AS, Young A, Tosoian JJ, Ghabili K, Andreas D, Klein E, Ross AE, Macura KJ
Journal of Urology, 2017.
PSMA-targeted 18F-DCFPyL PET/CT in the Preoperative Staging of Men with High-risk Prostate Cancer: Results of a Prospective Phase II Single-Center Study
Gorin MA, Rowe SP, Patel HD, Vidal I, Mana-Ay M, Javadi MS, Solnes LB, Ross AE, Schaeffer EM, Bivalacqua TJ, Partin AW, Pienta KJ, Szabo Z, De Marzo AM, Pomper MG, Allaf ME
Journal of Urology, 2017.
Predictors and Patterns of Regional Recurrence Following Lung SBRT: A Report From the Elekta Lung Research Group.
Giuliani M, Hope A, Mangona VS, Guckenberger M, Mantel F, Peulen H, Sonke J, Belderbos J, Werner-Wasik M, Ye H, Grills IS.
Clinical Lung Cancer, 2016.
Efficacy of post-operative radiation in a prostatectomy cohort adjusted for clinical and genomic risk
Ross AE, Den RB, Yousefi K, Trock BJ, Tosoian J, Davicioni E, Thompson DJ, Choeurng V, Haddad Z, Tran PT, Trabulsi EJ, Gomella LG, Lallas CD, Abdollah F, Feng FY, Klein EA, Dicker AP, Freedland SJ, Karnes RJ, Schaeffer EM
Prostate Cancer Prostatic Diseases, 2016.
Molecular analysis of low grade prostate cancer utilizing a genomic classifier of metastatic potential
Klein EA, Santiago-Jiménez M, Yousefi K, Robbins BA, Schaeffer EM, Trock BJ, Tosoian J, Haddad Z, Ra S, Karnes RJ, Jenkins RB, Cheville JC, Den RB, Dicker AP, Davicioni E, Freedland SJ, Ross AE
Journal of Urology , 2016.
Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer:  a matched retrospective analysis
Zhao SG, Chang SL, Spratt DE, Erho N, Yu M, Ashab HA, Alshalalfa M, Speers C, Tomlins SA, Davicioni E, Dicker AP, Carroll PR, Cooperberg MR, Freedland SJ, Karnes RJ, Ross AE, Schaeffer EM, Den RB, Nguyen PL, Feng FY
Lancet Oncology, 2016.
Multigene Testing in Localized Prostate Cancer
Ashley E. Ross, MD, PhD
Journal of the National Comprehensive Cancer Network, 2016.
Oligometastatic prostate cancer: definitions, clinical outcomes and treatment considerations
Tosoian JJ, Gorin MA, Ross AE, Pienta KJ, Tran PT, Schaeffer EM
Nature Reviews Urology, 2016.
Towards effective and efficient patient-specific quality assurance for spot-scanning proton therapy
Zhu XR, Li Y, Mackin D, Li H, Poenisch F, Lee AK, Mahajan A, Frank SJ, Gillin MT, Sahoo N, Zhang X
Cancers, 2015.
Changes in Pulmonary Function Following Image Guided Stereotactic Lung Radiotherapy: Neither Lower Baseline or Post-SBRT Pulmonary Function are Associated with Worse Overall Survival.
Stone BS, Mangona VS, Johnson MD, Ye Hong, Grills IS
Journal of Thoracic Oncology, 2015.
Toxicity After Central versus Peripheral Stereotactic Lung Radiotherapy (SBRT): A Propensity Score Matched-Pair Analysis.
Mangona VS, Aneese AM, Hymas RV, Marina 0, lonascu D, Gallardo LJ, Yan D, Robertson JM, Grills IS
International Journal of Radiation Oncology, Biology and Physics, 2015.
Real-time in vivo rectal wall dosimetry using plastic scintillation detectors for patients with prostate cancer
Wootton L, Kudchadker R, Lee A, Beddar S
Physics in Medicine and Biology, 2014.
Risk of late toxicity in men receiving dose-escalated hypofractionated intensity modulated prostate radiation therapy: results from a randomized trial
Hoffman KE, Voong KR, Pugh TJ, Skinner H, Levy LB, Takiar V, Choi S, Du W, Frank SJ, Johnson J, Kanke J, Kudchadker RJ, Lee AK, Mahmood U, McGuire SE, Kuban DA
International Journal of Radiation Oncology, 2014.
The Influence of Age and Comorbidity on the Benefit of Adding Androgen Deprivation to Dose-escalated Radiation in Men With Intermediate-risk Prostate Cancer
Bian SX, Kuban DA, Levy LB, Oh J, Choi S, McGuire SE, Frank SJ, Mahmood U, Nguyen PL, Pugh TJ, Lee AK, Hoffman KE
American Journal of Clinical Oncology, 2014.
Current Clinical Presentation and Treatment of Localized Prostate Cancer in the United States
Mahmood U, Levy LB, Nguyen PL, Lee AK, Kuban DA, Hoffman KE
Journal of Urology, 2014.
Impact of a clinical trial initiative on clinical trial enrollment in a multidisciplinary prostate cancer clinic
Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE
Journal of the National Comprehensive Cancer Network, 2014.
A single-field integrated boost treatment planning technique for spot scanning proton therapy
Zhu XR, Poenisch F, Li H, Zhang X, Sahoo N, Wu RY, Li X, Lee AK, Chang EL, Choi S, Pugh T, Frank SJ, Gillin MT, Mahajan A, Grosshans DR
Radiation Oncology, 2014.
Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum.
Sturgeon JD, Crane CH, Krishnan S, Minsky BO, Skibber JM, Rodriguez-Bigas MA, Chang GJ, You YN, Eng C, Das P.
American Journal of Clinical Oncology, 2014.
Improved human observer performance in digital reconstructed radiograph verification in head and neck cancer radiotherapy.
Sturgeon JD; Cox JA; Mayo LL; Gunn GB; Zhang J; Balter PA; Dong L; Awan M; Kocak-Uzel E; Mohamed AS; Rosenthal DI; Fuller CD.
International Journal of Computer Assisted Radiology and Surgery, 2014.
Use of treatment log files in spot scanning proton therapy as part of patient-specific quality assurance
Li H, Sahoo N, Poenisch F, Suzuki K, Li Y, Li X, Zhang X, Lee AK, Gillin MT, Zhu XR
Medical Physics, 2013.
Establishing and expanding the indications for proton and particle therapy
Muren L, Rossi C, Hug E, Lee AK, Glimelius B
Acta Oncologica, 2013.
Multifield optimization intensity-modulated proton therapy (MFO-IMPT) for prostate cancer: Robustness analysis through simulation of rotational and translational alignment errors
Pugh TJ, Amos RA, John Baptiste S, Choi S, Nhu Nguyen Q, Ronald Zhu X, Palmer MB, Lee AK
Medical Dosimetry, 2013.
A Fully Automated Method for CT-on-Rails-Guided Online Adaptive Planning for Prostate Cancer Intensity Modulated Radiation Therapy
Li X, Quan EM, Li Y, Pan X, Zhou Y, Wang X, Du W, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X
International Journal of Radiation Oncology, 2013.
Factors associated with improved biochemical response to neoadjuvant androgen deprivation therapy before definitive radiation therapy in prostate cancer patients
Cerne JZ, McGuire SE, Grant SR, Munsell MF, Lee AK, Kudchadker RJ, Choi SL, Mahmood U, Hoffman KE, Pugh TJ, Frank SJ, Kuban DA
Prostate Cancer and Prostatic Diseases, 2013.
Statistical Assessment of Proton Treatment Plans under Setup and Range Uncertainties
Park PC, Cheung JP, Zhu XR, Lee AK, Sahoo N, Tucker SL, Liu W, Li H, Mohan R, Court LE, Dong L
International Journal of Radiation Oncology, 2013.
Declining use of brachytherapy for the treatment of prostate cancer
Mahmood U, Pugh T, Frank S, Levy L, Walker G, Haque W, Koshy M, Graber W, Swanson D, Hoffman K, Kuban D, Lee A
Brachytherapy, 2013.
Anatomic variation and dosimetric consequences of neoadjuvant hormone therapy before radiation therapy for prostate cancer
Melancon AD, Lee AK, Kudchadker R, Zhang L, Tucker S, Kuban D, Dong L
Practical Radiation Oncology, 2013.
Core Physics Competencies for Proton Therapy Training of Radiation Oncology and Medical Physics Residents and Fellows
Winey B, Shih B, Sahoo N, Lee A, Vapiwala N, Both S
International Journal of Radiation Oncology, 2013.
Quality of Life and Toxicity From Passively Scattered and Spot-Scanning Proton Beam Therapy for Localized Prostate Cancer
Pugh TJ, Munsell MF, Choi S, Nguyen QN, Mathai B, Zhu XR, Sahoo N, Gillin M, Johnson JL, Amos RA, Dong L, Mahmood U, Kuban DA, Frank SJ, Hoffman KE, McGuire SE, Lee AK
International Journal of Radiation Oncology, 2013.
Dosimetric Effects of Weight Loss or Gain During Volumetric-Modulated Arc Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer
Pair ML, Du W, Rojas HD, Kanke JE, McGuire SE, Lee AK, Kuban DA, Kudchadker RJ
Medical Dosimetry, 2013.
Real-time catheter tracking for high-dose-rate prostate brachytherapy using an electromagnetic 3D-guidance device: A preliminary performance study.
Zhou J, Sebastian E, Mangona V, Yan D
Medical Physics, 2013.
Verification of proton range, position, and intensity in IMPT with a 3D liquid scintillator detector system
Archambault L, Poenisch F, Sahoo N, Robertson D, Lee A, Gillin MT, Mohan R, Beddar S
Medical Physics, 2012.
Proton beam therapy for the treatment of prostate cancer
Pugh TJ, Choi S, Nguyen QN, Gillin M, Zhu R, Palmer M, Lee AK
Practical Radiation Oncology, 2012.
A Comprehensive Comparison of IMRT and VMAT Plan Quality for Prostate Cancer Treatment
Quan EM, Li X, Li Y, Wang X, Kudchadker RJ, Johnson JL, Kuban DA, Lee AK, Zhang X
International Journal of Radiation Oncology, 2012.
Is Androgen Deprivation Therapy Necessary in All Intermediate-Risk Prostate Cancer Patients Treated in the Dose Escalation Era?
Castle KO, Hoffman KE, Levy LB, Lee AK, Choi S, Nguyen QN, Frank SJ, Pugh TJ, McGuire SE, Kuban DA
International Journal of Radiation Oncology , 2012.
Prostate cancer-specific mortality after definitive radiation therapy: who dies of disease?
Kim MM, Hoffman KE, Levy LB, Frank SJ, Pugh TJ, Choi S, Nguyen QN, McGuire SE, Lee AK, Kuban DA
European Journal of Cancer, 2012.
Screening Colonoscopy Before Prostate Cancer Treatment Can Detect Colorectal Cancers in Asymptomatic Patients and Reduce the Rate of Complications After Brachytherapy
Sharp H, Swanson D, Pugh TJ, Zhang M, Phan J, Kudchadker R, Bruno T, Kuban D, Lee AK, Choi S, Nguyen QN, Hoffman K, McGuire S, Frank S
Practical Radiation Oncology, 2012.
Uncertainty incorporated beam angle optimization for IMPT treatment planning
Cao W, Lim GJ, Lee A, Li Y, Liu W, Ronald Zhu X, Zhang X
Medical Physics, 2012.
Addition of short-term androgen deprivation therapy to dose-escalated radiation therapy improves failure-free survival for select men with intermediate-risk prostate cancer
Bian SX, Kuban DA, Levy LB, Oh J, Castle KO, Pugh TJ, Choi S, McGuire SE, Nguyen QN, Frank SJ, Nguyen PL, Lee AK, Hoffman KE
Annals of Oncology, 2012.
Effectiveness of a novel gas-release endorectal balloon in the removal of rectal gas for prostate proton radiation therapy
Wootton L, Kudchadker R, Beddar A, Lee AK
Journal of Applied Clinical Medical Physics, 2012.
In-phantom dose verification of prostate IMRT and VMAT deliveries using plastic scintillation detectors
Klein D, Briere TM, Kudchadker R, Archambault L, Beaulieu L, Lee A, Beddar S
Radiation Measurements, 2012.
Risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer
Rechner LA, Howell RM, Zhang R, Etzel C, Lee AK, Newhauser WD
Physics in Medicine and Biology, 2012.
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era
McGuire SE, Lee AK, Cerne JZ, Munsell MF, Levy LB, Kudchadker RJ, Choi SL, Nguyen QN, Hoffman KE, Pugh TJ, Frank SJ, Corn PG, Logothetis CJ, Kuban DA
International Journal of Radiation Oncology, 2012.
Endorectal magnetic resonance imaging for predicting pathologic T3 disease in Gleason score 7 prostate cancer: Implications for prostate brachytherapy
Pugh TJ, Frank SJ, Achim M, Kuban DA, Lee AK, Hoffman KE, McGuire SE, Swanson DA, Kudchadker R, Davis JW
Brachytherapy, 2012.
Characterization of dose impact on IMRT and VMAT from couch attenuation for two Varian couches
Heng L, Lee AK, Johnson J, Zhu R, Kudchadker R
Journal of Applied Clinical Medical Physics, 2011.
Long-term Failure Patterns and Survival in a Randomized Dose-Escalation Trial for Prostate Cancer. Who Dies of Disease? 
Kuban DA, Levy LB, Cheung MR, Lee AK, Choi S, Frank S, Pollack A
International Journal of Radiation Oncology, 2011.
Patient-Specific Quality Assurance for Prostate Cancer Patients Receiving Spot Scanning Proton Therapy Using Single-Field Uniform Dose
Zhu XR, Poenisch F, Song X, Johnson JL, Ciangaru G, Taylor MB, Lii M, Martin C, Arjomandy B, Lee AK, Choi S, Nguyen QN, Gillin MT, Sahoo N
International Journal of Radiation Oncology, 2011.
Role of radiation therapy for the treatment of lymph nodes in urologic malignancies
Pugh TJ, Lee AK
Urologic Clinics of North America, 2011.
Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer
Choi S, Lee AK
Journal of Drug, Healthcare and Patient Safety, 2011.
A Beam-specific Planning Target Volume (PTV) Design for Proton Therapy to Account for Setup and Range Uncertainties
Park PC, Zhu XR, Lee AK, Sahoo N, Melancon AD, Zhang L, Dong L
International Journal of Radiation Oncology, 2011.
Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy
Vassiliev ON, Kudchadker RJ, Kuban DA, Frank SJ, Choi S, Nguyen Q, Lee AK
Physica Medica, 2011.
A volumetric trend analysis of the prostate and seminal vesicles during a course of intensity-modulated radiation therapy
Frank SJ, Kudchadker RJ, Kuban DA, De Crevoisier R, Lee AK, Cheung RM, Choi S, Tucker SL, Dong L
American Journal of Clinical Oncology, 2010.
Toward a real-time in vivo dosimetry system using plastic scintillation detectors
Archambault L, Briere TM, Pönisch F, Beaulieu L, Kuban DA, Lee A, Beddar S
International Journal of Radiation Oncology, 2010.
Spot Scanning Proton Beam Therapy for Prostate Cancer: Treatment Planning Technique and Analysis of Consequences of Rotational and Translational Alignment Errors
Meyer J, Bluett J, Amos R, Levy L, Choi S, Nguyen QN, Zhu XR, Gillin M, Lee A
International Journal of Radiation Oncology, 2010.
Late Rectal Toxicity on RTOG 94-06: Analysis Using a Mixture Lyman Model
Tucker SL, Dong L, Bosch WR, Michalski J, Winter K, Mohan R, Purdy JA, Kuban D, Lee AK, Cheung MR, Thames HD, Cox JD
International Journal of Radiation Oncology, 2010.
Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer
Cheung J, Kudchadker RJ, Zhu XR, Lee AK, Newhauser WD
Physics in Medicine and Biology, 2010.
Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.
Grills IS, Mangona VS, Welsh R, Chmielewski G, Mcinerney E, Martin S, et al.
Journal of Clinical Oncology, 2010.
Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy
Frank SJ, Levy LB, Kuban DA, Lee AK, Kudchadker RJ, Bruno TL, van Vulpen M, Swanson DA
Journal of Urology, 2009.
Risk of secondary malignant neoplasms from proton therapy and intensity-modulated x-ray therapy for early-stage prostate cancer
Fontenot JD, Lee AK, Newhauser WD
International Journal of Radiation Oncology, 2009.
The MD Anderson Proton Therapy System
Smith A, Gillin M, Bues M, Zhu XR, Suzuki K, Mohan R, Woo S, Lee A, Komaki R, Cox J, Hiramoto K, Akiyama H, Ishida T, Sasaki T, Matsuda K
Medical Physics, 2009.
Urinary side effects and complications after permanent prostate brachytherapy: the MD Anderson Cancer Center experience
Anderson JF, Swanson DA, Levy LB, Kuban DA, Lee AK, Kudchadker R, Phan J, Bruno T, Frank SJ
Urology, 2009.
Can digital rectal examination or transrectal ultrasonography biopsy findings predict the side of nodal metastasis in prostate cancer?
Spiess PE, Busby JE, Jordan JJ, Steinberg JR, Bassett RL, Davuluri R, Burt K, Troncoso P, Lee AK, Taylor SH, Pisters LL
Urologic Oncology, 2008.
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer
Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A
International Journal of Radiation Oncology, 2008.
Reducing stray radiation dose to patients receiving passively scattered proton radiotherapy for prostate cancer
Taddei PJ, Fontenot JD, Zheng Y, Mirkovic D, Lee AK, Titt U, Newhauser WD
Physics in Medicine and Biology, 2008.
Prostate Specific Antigen Working Group guidelines on prostate specific antigen doubling time
Arlen PM, Bianco F, Dahut WL, D'Amico A, Figg WD, Freedland SJ, Gulley JL, Kantoff PW, Kattan MW, Lee A, Regan MM, Sartor O, Prostate Specific Antigen Working Group
Journal of Urology, 2008.
Dosimetric Changes Resulting From Patient Rotational Setup Errors in Proton Therapy Prostate Plans
Sejpal SV, Amos RA, Bluett JB, Levy LB, Kudchadker RJ, Johnson J, Choi S, Lee AK
International Journal of Radiation Oncology, 2008.
Hemostatic and Inflammatory Risk Factors for Intracerebral Hemorrhage in a Pooled Study.
Sturgeon JD; Folsom AR; Longstreth WT; Shahar E; Rosamond WO; Cushman M.
Stroke, 2008.
Effect of anatomic motion on proton therapy dose distributions in prostate cancer treatment
Zhang X, Dong L, Lee AK, Cox JD, Kuban DA, Zhu RX, Wang X, Li Y, Newhauser WD, Gillin M, Mohan R
International Journal of Radiation Oncology , 2007.
Surgically managed lymph node-positive prostate cancer: does delaying hormonal therapy worsen the outcome?
Spiess PE, Lee AK, Busby JE, Jordan JJ, Hernandez M, Burt K, Troncoso P, Merriman KW, Pisters LL
BJU International, 2007.
Changes in the pelvic anatomy after an IMRT treatment fraction of prostate cancer
de Crevoisier R, Melancon AD, Kuban DA, Lee AK, Cheung RM, Tucker SL, Kudchadker RJ, Newhauser WD, Zhang L, Mohan R, Dong L
International Journal of Radiation Oncology, 2007.
Commentary on "Cancer Specific Mortality After Radiation Therapy with Short-Course Hormonal Therapy or Radical Prostatectomy in Men with Localized, Intermediate-Risk to High-Risk Prostate Cancer"
Lee AK
The American Journal of Hematology/Oncology, 2007.
Implication of CT table sag on geometrical accuracy during virtual simulation
Zullo JR, Kudchadker R, Wu R, Lee A, Prado K
Medical Dosimetry, 2007.
Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer
Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, Kudchadker RJ, Thames H, Mohan R, Kuban D
International Journal of Radiation Oncology, 2007.
Is a 3-mm intrafractional margin sufficient for daily image-guided intensity-modulated radiation therapy of prostate cancer?
Melancon AD, O'Daniel JC, Zhang L, Kudchadker RJ, Kuban DA, Lee AK, Cheung RM, de Crevoisier R, Tucker SL, Newhauser WD, Mohan R, Dong L
Radiotherapy & Oncology, 2007.
Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate
Newhauser W, Fontenot J, Koch N, Dong L, Lee A, Zheng Y, Waters L, Mohan R
Physics in Medicine and Biology, 2007.
Using prostate-specific antigen doubling time in clinical practice
Lee AK, D'Amico AV
BJU International, 2007.
Risk Factors for lntracerebral Hemorrhage in a Pooled Prospective Study.
Sturgeon JD; Folsom AR; Longstreth WT; Shahar E; Rosamond WO; Cushman M.
Stroke, 2007.
Trends in the hospitalization rate, hospital case fatality, and mortality rate of stroke by subtype in Minneapolis-St Paul.
Sturgeon JD; Folsom AR
Neuroepidemiology, 2007.
Late gastrointestinal toxicity after radiation for prostate cancer
Giordano SH, Lee A, Kuo YF, Freeman J, Goodwin JS
Cancer, 2006.
Presalvage prostate-specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy
Spiess PE, Lee AK, Leibovici D, Wang X, Do KA, Pisters LL
Cancer, 2006.
Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer
Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA
Cancer, 2006.
Update on radiation therapy in prostate cancer
Lee AK, Frank SJ
Hematology/Oncology Clinics of North America, 2006.
Dosimetric comparison of four target alignment methods for prostate cancer radiotherapy
O'Daniel JC, Dong L, Zhang L, de Crevoisier R, Wang H, Lee AK, Cheung R, Tucker SL, Kudchadker RJ, Bonnen MD, Cox JD, Mohan R, Kuban DA
International Journal of Radiation Oncology , 2006.
Reducing metal artifacts in cone-beam CT images by preprocessing projection data
Zhang Y, Zhang L, Zhu XR, Lee AK, Chambers M, Dong L
International Journal of Radiation Oncology, 2006.
Radiation therapy combined with hormone therapy for prostate cancer
Lee AK
Seminars in Radiation Oncology, 2006.
Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy
Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA 
International Journal of Radiation Oncology, 2005.
Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy
Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D
International Journal of Radiation Oncology, 2005.
Implementation and validation of a three-dimensional deformable registration algorithm for targeted prostate cancer radiotherapy
Wang H, Dong L, Lii MF, Lee AL, de Crevoisier R, Mohan R, Cox JD, Kuban DA, Cheung R
International Journal of Radiation Oncology, 2005.
Symptomatic local recurrence of prostate carcinoma after radiation therapy
Leibovici D, Lee AK, Cheung RM, Spiess PE, Kuban DA, Rosser CJ, Shen Y, Yang Y, Chichakli R, Pisters LL
Cancer, 2005.
Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer?
Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL
Urology, 2005.
Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy
Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters L, Babaian RJ, Kuban D
International Journal of Radiation Oncology, 2005.
Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy
Lee AK, Levy LB, Cheung R, Kuban D
International Journal of Radiation Oncology, 2005.
Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy
Lee AK, D'Amico AV
Journal of Clinical Oncology, 2005.
Comparison of treatment volumes and techniques in prostate cancer radiation therapy
Lee CT, Dong L, Ahamad AW, Choi H, Cheung R, Lee AK, Horne DF, Breaux AJ, Kuban DA
American Journal of Clinical Oncology, 2005.
Mortality after cure of testicular seminoma
Zagars GK, Ballo MT, Lee AK, Strom SS
Journal of Clinical Oncology, 2004.
In vivo tumor imaging in mice with near-infrared labeled endostatin
Citrin D, Lee AK, Scott T, Sproull M, Ménard C, Tofilon PJ, Camphausen K
Molecular Cancer Therapeutics, 2004.
Evaluation of a contour-alignment technique for CT-guided prostate radiotherapy: an intra- and interobserver study
Court LE, Dong L, Taylor N, Ballo M, Kitamura K, Lee AK, O'Daniel J, White RA, Cheung R, Kuban D
International Journal of Radiation Oncology, 2004.
Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure
Kamat AM, Rosser CJ, Levy LB, Chichakli R, Lee AK, Cheung MR, Pisters LL
Urology, 2004.
Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer
Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL
Journal of the National Medical Association, 2004.
Can the core length involved with prostate cancer identify clinically insignificant disease in low risk patients diagnosed on the basis of a single positive core?
Lee AK, Doytchinova T, Chen MH, Renshaw AA, Weinstein M, Richie JP, D'Amico AV
Urologic Oncology, 2003.
Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma
Rosser CJ, Reyes AO, Vakar-Lopez F, Levy LB, Kuban DA, Hoover DC, Lee AK, Pisters LL
International Journal of Radiation Oncology, 2003.
Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate
Rosser CJ, Levy LB, Kuban DA, Chichakli R, Pollack A, Lee A, Pisters LL
Journal of Urology, 2003.
Current results of brachytherapy for soft tissue sarcoma
Ballo MT, Lee AK
Current Opinion in Oncology, 2003.
Dosimetric consequences of using a surrogate urethra to estimate urethral dose after brachytherapy for prostate cancer
Lee HK, D'Souza WD, Yamal JM, Pollack A, Lee AK, Palmer MB, Kuban DA
International Journal of Radiation Oncology, 2003.
Utility of the percentage of positive prostate biopsies in predicting PSA outcome after radiotherapy for patients with clinically localized prostate cancer
Selek U, Lee A, Levy L, Kuban DA
International Journal of Radiation Oncology, 2003.
Uncertainties in physical and biological targeting with radiation therapy
Cox JD, Schechter NR, Lee AK, Forster K, Stevens CW, Ang KK, Komaki R, Liao Z, Milas L
Rays, 2003.
Toward a better understanding of the comparatively high prostate cancer incidence rates in Utah.
Merill RM; Hilton SC; Wiggins CL; Sturgeon JD
BMC Cancer, 2003.
Apolipoprotein E Genotype and Incident lschemic Stroke. The Athersosclerosis Risk in Communities Study.
Sturgeon JD; Folsom AR; Bray MS; Boerwinkle E; Ballantyne CM
Stroke, 2003.
Prostate specific antigen bounce phenomenon after external beam radiation for clinically localized prostate cancer
Rosser CJ, Kuban DA, Levy LB, Chichakli R, Pollack A, Lee AK, Pisters LL
Journal of Urology, 2002.
Optimizing patient selection for prostate monotherapy
Lee AK, Schultz D, Renshaw AA, Richie JP, D'Amico AV
International Journal of Radiation Oncology, 2001.
Stereotactic radiosurgery for patients with single brain metastasis
Cho K, Hall W, Lee A, Gerbi B, Higgins P, Bohen M, Nussbaum E
Journal of Radiosurgery, 1998.
Characterization of the three-compartment gel-entrapment porcine hepatocyte bioartificial liver
Sielaff TD, Nyberg SL, Rollins MD, Hu MY, Amiot B, Lee A, Wu FJ, Hu WS, Cerra FB
Cell Biology and Toxicology, 1997.

Texas Center for Proton Therapy is ready to help you fight cancer with one of the nation’s most advanced cancer-fighting technologies.

Request an Appointment